Logo image of CRVS

CORVUS PHARMACEUTICALS INC (CRVS) Stock Fundamental Analysis

NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock - Currency: USD

3.47  -0.16 (-4.41%)

After market: 3.58 +0.11 (+3.17%)

Fundamental Rating

2

CRVS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 561 industry peers in the Biotechnology industry. CRVS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CRVS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CRVS has reported negative net income.
In the past year CRVS has reported a negative cash flow from operations.
CRVS had negative earnings in each of the past 5 years.
In the past 5 years CRVS always reported negative operating cash flow.
CRVS Yearly Net Income VS EBIT VS OCF VS FCFCRVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -90.40%, CRVS is not doing good in the industry: 74.15% of the companies in the same industry are doing better.
CRVS has a worse Return On Equity (-191.27%) than 67.56% of its industry peers.
Industry RankSector Rank
ROA -90.4%
ROE -191.27%
ROIC N/A
ROA(3y)-70.1%
ROA(5y)-51.36%
ROE(3y)-111.59%
ROE(5y)-77.52%
ROIC(3y)N/A
ROIC(5y)N/A
CRVS Yearly ROA, ROE, ROICCRVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CRVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRVS Yearly Profit, Operating, Gross MarginsCRVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

5

2. Health

2.1 Basic Checks

CRVS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRVS has more shares outstanding
There is no outstanding debt for CRVS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRVS Yearly Shares OutstandingCRVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
CRVS Yearly Total Debt VS Total AssetsCRVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

Based on the Altman-Z score of -4.97, we must say that CRVS is in the distress zone and has some risk of bankruptcy.
CRVS has a Altman-Z score of -4.97. This is in the lower half of the industry: CRVS underperforms 60.61% of its industry peers.
CRVS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.97
ROIC/WACCN/A
WACCN/A
CRVS Yearly LT Debt VS Equity VS FCFCRVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

CRVS has a Current Ratio of 1.54. This is a normal value and indicates that CRVS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of CRVS (1.54) is worse than 81.46% of its industry peers.
A Quick Ratio of 1.54 indicates that CRVS should not have too much problems paying its short term obligations.
The Quick ratio of CRVS (1.54) is worse than 80.93% of its industry peers.
Industry RankSector Rank
Current Ratio 1.54
Quick Ratio 1.54
CRVS Yearly Current Assets VS Current LiabilitesCRVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CRVS have decreased strongly by -17.31% in the last year.
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%275%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 19.92% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y50.63%
EPS Next 2Y14.16%
EPS Next 3Y8.81%
EPS Next 5Y19.92%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CRVS Yearly Revenue VS EstimatesCRVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
CRVS Yearly EPS VS EstimatesCRVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CRVS. In the last year negative earnings were reported.
Also next year CRVS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRVS Price Earnings VS Forward Price EarningsCRVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRVS Per share dataCRVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y14.16%
EPS Next 3Y8.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRVS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CORVUS PHARMACEUTICALS INC

NASDAQ:CRVS (5/22/2025, 8:00:00 PM)

After market: 3.58 +0.11 (+3.17%)

3.47

-0.16 (-4.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04
Inst Owners43.45%
Inst Owner Change-3.14%
Ins Owners3.91%
Ins Owner Change19.7%
Market Cap236.55M
Analysts86.67
Price Target15.3 (340.92%)
Short Float %10.69%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-226.02%
Min EPS beat(2)-404.49%
Max EPS beat(2)-47.55%
EPS beat(4)2
Avg EPS beat(4)-96.05%
Min EPS beat(4)-404.49%
Max EPS beat(4)65.9%
EPS beat(8)4
Avg EPS beat(8)-50.08%
EPS beat(12)6
Avg EPS beat(12)-42.09%
EPS beat(16)8
Avg EPS beat(16)-30.97%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.32%
EPS NY rev (1m)8.96%
EPS NY rev (3m)7.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 7.26
P/tB 7.26
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.65
Fwd EYN/A
FCF(TTM)-0.37
FCFYN/A
OCF(TTM)-0.37
OCFYN/A
SpS0
BVpS0.48
TBVpS0.48
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -90.4%
ROE -191.27%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-70.1%
ROA(5y)-51.36%
ROE(3y)-111.59%
ROE(5y)-77.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.54
Quick Ratio 1.54
Altman-Z -4.97
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-17.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%275%
EPS Next Y50.63%
EPS Next 2Y14.16%
EPS Next 3Y8.81%
EPS Next 5Y19.92%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-6.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.22%
OCF growth 3YN/A
OCF growth 5YN/A